Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
| Autor: | Philippe Menei, Milad Pourbaghi-Masouleh, Emilie Roger, Anne Clavreul |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Angiogenesis
Biophysics Pharmaceutical Science Bioengineering 02 engineering and technology 010402 general chemistry 01 natural sciences Biomaterials Delivery methods chemistry.chemical_compound Drug Discovery Medicine business.industry Organic Chemistry General Medicine 021001 nanoscience & nanotechnology medicine.disease 3. Good health 0104 chemical sciences Angiogenesis inhibitor Clinical trial Vascular endothelial growth factor chemistry Tumor progression Cancer research Nanocarriers 0210 nano-technology business Glioblastoma |
| Zdroj: | International Journal of Nanomedicine. 14:2497-2513 |
| ISSN: | 1178-2013 |
| DOI: | 10.2147/ijn.s194858 |
| Popis: | Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the development of viral and nonviral delivery methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, including convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial (orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce the clinical scenario of tumor progression and therapy response encountered in GB patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|